

**CUMBERLAND<sup>®</sup>**  
P H A R M A C E U T I C A L S

---

Corporate Presentation

Nasdaq CPIX

# Safe Harbor Statement

This presentation contains forward-looking statements concerning our approved products and product development, our technology, our competitors, our intellectual property, our financial condition and our plans for research and development programs that involve risks, uncertainties and assumptions. These statements are based on the current estimates and assumptions of the management of Cumberland Pharmaceuticals as of the date of this presentation and are subject to uncertainty and changes in circumstances. Given these uncertainties, you should not place undue reliance upon these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties, assumptions and other factors that may cause the actual results of Cumberland Pharmaceuticals to be materially different from those reflected in such forward-looking statements.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, those set forth under the headings "Risk factors" and "Management's discussion and analysis of financial condition and results of operations" in our Form 10-K and Form 10-Q Reports on file with the SEC. The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. All statements contained in this presentation are made only as of the date of this presentation. For more information on our brands, including full prescribing and safety information, please see the links to the product websites which can be found at [www.cumberlandpharma.com](http://www.cumberlandpharma.com).



# Company Overview

- **Specialty pharmaceutical company**
  - Portfolio of **seven** FDA approved products
  - Promoted by **two** national sales forces
- Several **near-term catalysts** for new growth opportunities
  - **Vibativ** post-acquisition integration and market expansion
  - **Next Generation Caldolor** product launch
  - **RediTrex** methotrexate product line launch
- **Phase II candidates** in development with upcoming study milestones
- Proven record of **successful** product development and product acquisition



# Mission & Strategy

---

**Mission:** *Advance Patient Care  
through delivery of high quality medicines*

---

**Strategy:** *Build a portfolio of  
Specialized biopharmaceutical brands*

---



# Product Portfolio

---

Product  
Development:

*IV* **ACETADOTE**<sup>®</sup>

**CALDOLOR**<sup>®</sup>

**RediTrex**<sup>®</sup>

---

Product  
Acquisition:

 **KRISTALOSE**<sup>®</sup>

 **VIBATIV**<sup>®</sup>  
(telavancin) for injection

**Omeclamox-Pak**<sup>®</sup>

 **Vaprisol**<sup>®</sup>



# IV ACETADOTE<sup>®</sup>

- IV treatment for **America's leading cause of poisoning**
- **Treats liver toxicity** associated with acetaminophen overdose
- Developed and registered by **Cumberland**
- Acetadote now **standard of care**
- Cumberland developed **unique EDTA free formulation**
- Maintaining **significant market share**




*\*National Poison Data System, American Association of Poison Centers*



# CALDOLOR®

- **Injectable** delivery of **ibuprofen**
- **Developed** and **registered** by Cumberland
- **Antipyretic, analgesic & anti-inflammatory** properties
- Evaluated in **published studies** with ~ **2,000 patients**
- Over **2.3 million doses** administered
- **Pediatric labeling** approved by FDA
- Study in **newborns** recently completed


\*Symphony Source Health





# CALDOLOR®

- New, **ready to administer** without further dilution
- Designed to help address **National Opioid Crisis**
- **First and only FDA-approved** pre-mixed bag of ibuprofen
- Completed a **soft-launch**
- **National launch underway**, gaining early acceptance and growing demand
- Aim to **significantly grow Caldolor's sales** volume over time with the advantages of this ready-to-use product





- **Unique** crystalline formulation of lactulose
- Prescription strength laxative
- **Clinically proven** increases in patient satisfaction
- Repositioned to reflect **branded status**
- New pricing allowed co-pay support and improved **Managed Care coverage**



# Commercial Portfolio Expansion Strategy



## IDENTIFY

*Late Stage Candidates*



## ACQUIRE

*Under-Promoted,  
Approved Brands*



## EXPAND

*Existing Products*



## DEVELOP

*Early-Stage Candidates*

**PRODUCT  
PORTFOLIO**



# Acquisition Initiative



## GOAL TO ADD ONE NEW PRODUCT PER YEAR

through business development initiative or internal product development



Active, ongoing initiative to identify, evaluate and acquire/license **new products** into the portfolio



Source opportunities through direct efforts and intermediaries



Seek commercial and late stage development assets that fit our **strategy and focus**

- Branded, Rx products in hospital acute care or gastroenterology
- Sales of **\$5-25 million or larger** with attractive margins



- **Acquired** following development by Astellas & Theravance
- Injectable antibiotic that treat serious, **life-threatening infections**
- **Hospital** product that **aligns well** with our current infrastructure
- New data demonstrates **superiority over vancomycin** in select patients with bacterial pneumonia.

\* Published in *Infectious Disease and Therapy*



- **New injectable** delivery of **methotrexate**
- Designed for the treatment of **arthritis** and **psoriasis**
- **Widely used** throughout Europe with a strong brand presence
- The U.S. methotrexate market is demonstrating **significant growth**
- **FDA-approved** and currently implementing soft launch
- Full launch planned for **Spring 2021**



# Ifetroban Overview

- Cumberland's first **new chemical entity (NCE)**
- A **potent, selective** antagonist of thromboxane receptor (TP<sub>r</sub>)
- Initially developed by **Bristol-Myers Squibb** as an anti-platelet agent
- **Safety is well-established** in 26 clinical studies with **over 1,300 subjects**
- Collaborating with **Vanderbilt, Harvard, Scripps** and other academic centers
- Cumberland successfully manufactures **both IV** and **oral formulations**



# Ifetroban Development Pipeline



**Boxaban®** (*aspirin-exacerbated respiratory disease*)

**Vasculan®** (*systemic sclerosis*)

**Dyscorban™** (*Duchenne muscular dystrophy*)





# Duchenne Muscular Dystrophy (DMD)


- **A rare, fatal, genetic neuromuscular disease** characterized by the progressive loss of muscle which results in deterioration of the skeleton, heart and lungs
- Cumberland is investigating ifetroban for the treatment of **cardiomyopathy** associated with DMD
- **New data** demonstrates ifetroban could prevent cardiac fibrosis and improve cardiac function – published **Journal American Heart Association**
- The **FDA** awarded just over \$1 million in **Orphan Drug Grant** funding for this unmet medical need
- **IND cleared** and **Phase II study** is now underway






**CET**<sup>®</sup>

**Cumberland** *Emerging Technologies*



# Expanding Our Product Portfolio



## Deploying a Multifaceted Strategy to Create Value



# Financial Overview

(\$ in millions, except per diluted share)

**Q3 2020**

Net Revenues	\$9.3
Cost of Products Sold	<u>2.2</u>
Gross Profit	<b>\$7.2</b>
Selling & Marketing	\$3.6
Research & Development	1.2
General Administrative	2.4
Amortization	<u>1.1</u>
Total Cost & Expenses	<b>\$10.5</b>
Discontinued Operations	0.8
Adjusted Earnings*	0.2
Adjusted Earnings* per diluted share	<b>\$0.02</b>

*\*Represents a non-GAAP financial measure.*



# Summary Balance Sheet

(\$ IN MILLIONS)

*As of Sept. 30, 2020*

CASH & SECURITIES	\$26.6
TOTAL ASSETS	96.0
TOTAL LIABILITIES	48.2
TOTAL EQUITY	47.8

*\*\$20 million available on revolving line of credit*

*\*Tax carry forward credits of \$44 million available*

*\*Continued Share Repurchase Program*



# Cumberland Moving Forward



Diverse product portfolio **with 7 FDA approved brands**



Proven **development and commercialization capabilities**



Various initiatives in place to support **near-term growth**




**Phase II** products in development with upcoming study milestones



**Valuation gap** given assets, cash, sales, and pipeline







**CUMBERLAND<sup>®</sup>**  
P H A R M A C E U T I C A L S

---

Nasdaq CPIX